Developments in the Therapeutic Applications of Bisphosphonates
- 1 July 1999
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 39 (7), 651-660
- https://doi.org/10.1177/00912709922008272
Abstract
The authors review the structural, pharmacologic, and clinical aspects of bisphosphonates, a class of drugs currently used to treat several disorders of bone and calcium metabolism. Pertinent literature on the bisphosphonates was reviewed with the help of a MEDLINE search and several bibliographies, including published clinical trials, monographs, and review articles. The bisphosphonates are analogs of pyrophosphate that, when given orally or intravenously, bind avidly to exposed bone mineral and disrupt bone turnover. These agents comprise three groups or generations, based on their potency and chemical structures. All three generations are effective in treating hypercalcemia, Paget's disease of bone, osteoporosis, and other disorders of accelerated bone turnover. The third‐generation agents have the greatest potency and offer the promise of a convenient way to suppress or prevent osseous metastasis in patients with certain malignancies. As a group, these agents are well tolerated and, when administered correctly, rarely cause toxicity. The bisphosphonates are safe and effective agents for the treatment of disorders of accelerated bone turnover.Keywords
This publication has 50 references indexed in Scilit:
- Effects of the Bisphosphonate Olpadronate in Patients With Carcinoma of the Prostate Metastatic to the SkeletonBone, 1998
- Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of boneBone, 1997
- Bisphosphonates: Mechanisms of Action and Clinical Use in Osteoporosis - An UpdateHormone and Metabolic Research, 1997
- Comparative Clinical Pharmacology and Therapeutic Use of Bisphosphonates in Metabolic Bone DiseasesDrugs, 1996
- Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?European Journal Of Cancer, 1996
- Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapyJournal of Bone and Mineral Research, 1995
- Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronateJournal of Clinical Endocrinology & Metabolism, 1993
- Oral tiludronate: Pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosisBone, 1992
- TREATMENT OF PAGET'S DISEASE BY WEEKLY INFUSIONS OF 3-AMINOHYDROXYPROPYLIDENE-1, 1-BISPHOSPHONATE (APD)Rheumatology, 1992
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990